<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025207</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02414</org_study_id>
    <secondary_id>CLB-30101</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CDR0000068938</secondary_id>
    <nct_id>NCT00025207</nct_id>
  </id_info>
  <brief_title>Gefitinib in Treating Patients With Malignant Mesothelioma</brief_title>
  <official_title>A Phase II Study Of ZD 1839 (NSC 715055, IND 61187) In Patients With Malignant Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of gefitinib in treating patients who have&#xD;
      malignant mesothelioma. Biological therapies such as gefitinib may interfere with the growth&#xD;
      of the tumor cells and slow the growth of malignant mesothelioma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the activity of gefitinib, in terms of failure-free survival, in patients with&#xD;
      malignant mesothelioma.&#xD;
&#xD;
      II. Determine the response rate in patients treated with this drug. III. Determine the&#xD;
      toxicity of this drug in these patients. IV. Determine the overall survival of patients&#xD;
      treated with this drug. V. Determine whether overexpression of epidermal growth factor&#xD;
      receptor and expression of cyclo-oxygenase-2 can predict the effectiveness of this drug in&#xD;
      these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral gefitinib once daily on days 1-21. Courses repeat every 3 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 2 months for 1 year and then every 6 months for up to 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 7-10 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who remain failure-free</measure>
    <time_frame>Time between the initiation of treatment and initial failure (disease progression, relapse, death), assessed up to 3 months</time_frame>
    <description>Kaplan-Meier's product limit estimator and curves will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>An exact binomial confidence interval will be generated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>For each type of toxicity experienced, the frequency of reported toxicity will be summarized by the most severe grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Kaplan-Meier's product limit estimator and curves will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival within patient subgroups defined in terms of epidermal growth factor receptor (EGFR) overexpression and cyclooxygenase-2 (COX-2) expression</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>An exact binomial confidence interval will be generated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Advanced Malignant Mesothelioma</condition>
  <condition>Epithelial Mesothelioma</condition>
  <condition>Recurrent Malignant Mesothelioma</condition>
  <condition>Sarcomatous Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Treatment (gefitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral gefitinib once daily on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (gefitinib)</arm_group_label>
    <other_name>Iressa</other_name>
    <other_name>ZD 1839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (gefitinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignant mesothelioma that is not amenable to curative&#xD;
             surgery or radiotherapy&#xD;
&#xD;
               -  Epithelial, sarcomatoid, or mixed subtype&#xD;
&#xD;
               -  Any site of origin (including, but not limited to, the pleura, peritoneum,&#xD;
                  pericardium, or tunica vaginalis) allowed&#xD;
&#xD;
          -  Measurable disease, defined as lesions that can be accurately measured in at least 1&#xD;
             dimension (longest diameter) as at least 20 mm with conventional techniques or at&#xD;
             least 10 mm with spiral CT scan&#xD;
&#xD;
               -  Must be outside prior radiation port&#xD;
&#xD;
               -  Lesions not considered measurable include the following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Inflammatory breast disease&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - CTC 0-1&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent active malignancy except nonmelanoma skin cancer&#xD;
&#xD;
               -  Disease considered not currently active if completely treated with less than a&#xD;
                  30% risk for relapse&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No prior epidermal growth factor receptor-inhibitor therapy&#xD;
&#xD;
          -  Prior intrapleural cytotoxic or sclerosing agents (including bleomycin) allowed&#xD;
&#xD;
          -  No prior systemic cytotoxic chemotherapy for malignant mesothelioma&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  At least 1 week since prior CYP3A4 inducers (e.g., dexamethasone, glucocorticoids,&#xD;
             progesterone)&#xD;
&#xD;
          -  No concurrent CYP3A4 inducers (e.g., dexamethasone)&#xD;
&#xD;
          -  No concurrent hormonal therapy (e.g., tamoxifen) except steroids for adrenal failure&#xD;
             or hormones for non disease-related conditions (e.g., insulin for diabetes)&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy, including for palliation&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
          -  At least 1 week since other prior CYP3A4 inducers (e.g., carbamazepine, ethosuximide,&#xD;
             griseofulvin, nafcillin, nelfinavir mesylate, nevirapine, oxcarbazepine,&#xD;
             phenobarbital, phenylbutazone, phenytoin, primidone, rifabutin, rifampin, rofecoxib,&#xD;
             St. John's Wort, sulfadimidine, sulfinpyrazone, or troglitazone)&#xD;
&#xD;
          -  No other concurrent CYP3A4 inducers&#xD;
&#xD;
          -  No concurrent CYP3A4 substrates or inhibitors&#xD;
&#xD;
          -  No other concurrent investigational agent&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent chlorpromazine, amiodarone, or chloroquine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramaswamy Govindan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer and Leukemia Group B</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>September 9, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2003</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

